Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.49 |
| ▸ | SGK1 | O00141 | 3/20 | 0.48 |
| ▸ | ACLY | P53396 | 2/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 4/20 | 0.42 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2119426 | 0.88 | SGK1 (0.45) | SLC22A12SGK1ACLYHSD11B1CYP11B1 | |
| SCHEMBL2119468 | 0.79 | ALDH1A1 (0.39) | PTGES2 | |
| SCHEMBL2117332 | 0.78 | KCNJ1 (0.44) | PTGES2 | |
| SCHEMBL2118346 | 0.77 | MAPT (0.40) | PTGES2 | |
| SCHEMBL2117057 | 0.76 | GHSR (0.46) | ACLYPTGES2HDAC1HDAC2 | |
| SCHEMBL2120149 | 0.76 | TRIM24 (0.48) | ALPLPTGES2 | |
| SCHEMBL2119785 | 0.75 | ACLY (0.59) | SGK1ACLYHSD11B1PTGES2 | |
| SCHEMBL2118327 | 0.74 | HSD11B1 (0.56) | ACLYHSD11B1PTGES2 | |
| SCHEMBL2116112 | 0.73 | MAPT (0.44) | SLC22A12CYP11B1CYP11B2ALPL | |
| SCHEMBL2119953 | 0.73 | ACLY (0.47) | SLC22A12ACLYHSD11B1PTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | ELARA PHARMACEUTICALS GMBH (DE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095012-A1 | TOLUIDINE SULFONAMIDES AND THEIR USE | HIF1A, HIF1AN, EGLN3 | SLC22A12 3075/4885SGK1 4188/4885ACLY 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.